



ESPERITE (ESP) resumes negotiations regarding proposed sale of stem cell banking business to PBKM

Amsterdam, The Netherlands – 13 June 2019

Esperite N.V. (Euronext: ESP, “Esperite”) announces today that it has resumed negotiations with Polski Bank Komórek Macierzystych S.A. (WSE: PBKM, “PBKM”) regarding the proposed sale of certain assets and liabilities related to Cryo-Save’s stem cell banking business (the Proposed Sale). The negotiations were resumed by Esperite after receiving an expression of renewed interest by PBKM, as announced today by PBKM. As of today, the parties have not yet reached agreement on the terms of the Proposed Sale.

As disclosed previously, the MoU regarding the Proposed Sale, including the exclusivity granted to PBKM, was terminated on 28 May 2019.

About ESPERITE

ESPERITE group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000.

To learn more about the *ESPERITE* Group, or to book an interview with CEO Frédéric Amar: [+31 575 548 998](tel:+31575548998) - ir@esperite.com.

This press release contains inside information as referred to in article 7 paragraph 1 of Regulation (EU) 596/2014 (Market Abuse Regulation).